<DOC>
	<DOCNO>NCT01132248</DOCNO>
	<brief_summary>Urinary schistosomiasis debilitate disease Central Africa pregnant woman frequently suffer condition . Mefloquine currently investigate preventive treatment malaria pregnancy mefloquine also know exert activity schistosomiasis . The investigator want test hypothesis whether mefloquine may active urinary schistosomiasis use preventive treatment malaria pregnancy .</brief_summary>
	<brief_title>Activity Mefloquine Against Urinary Schistosomiasis</brief_title>
	<detailed_description>Objectives The principal aim clinical trial evaluate whether mefloquine - give intermittent preventive treatment malaria pregnancy - show vivo activity concomitant Schistosoma haematobium infection . This study therefore `` proof principle '' study intend establish clinically satisfying cure rate formally compare efficacy mefloquine standard therapy . Hypothesis Two underlie hypothesis formulate proof principle study . Primary hypothesis : Mefloquine reduces egg excretion Schistosoma haematobium 50 % compare sulfadoxine/pyrimethamine ( S/P ) treatment give IPTp Secondary hypothesis : Mefloquine may lead adequate cure rate Schistosoma haematobium infection compare S/P ( &gt; 80 % ) Trial Design The evaluation mefloquine activity S. haematobium evaluate course open label multicenter randomize control trial assess efficacy , tolerability , safety mefloquine IPTp malaria . This study therefore nest randomize control trial take advantage randomization treatment allocation procedure IPTp trial assess additional efficacy outcome reduction S. haematobium egg excretion .</detailed_description>
	<mesh_term>Schistosomiasis</mesh_term>
	<mesh_term>Schistosomiasis haematobia</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>Pregnant woman first trimester 28th week pregnancy HIV negative Egg excretion Schistosoma haematobium ( mean &gt; 10 egg per mL urine ) Asymptomatic ( sign complicate Schistosomiasis , severe anemia ) Ability comply study protocol Intake anthelminthic antimalarial drug within 2 month prior inclusion Allergy study drug</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>schistosomiasis , schistosoma haematobium</keyword>
</DOC>